control group:Durvalumab

2 trials

Sponsors

The First Teaching Hospital of Tianjin University of TCM

Conditions

lung cancer

Early Phase 1

A randomized, controlled, single-center clinical study of Xiaoyan Decoction in combination with Durvalumab in the treatment of unresectable advanced NSCLC after radiotherapy and chemotherapy

RecruitingITMCTR2100004486

The First Teaching Hospital of Tianjin University of TCMlung cancer

Start: 2021-02-24Updated: 2023-02-20

Clinical study of Xiaoyan granule combined with Durvalumab in the treatment of advanced NSCLC

RecruitingChiCTR2100043656

The First Teaching Hospital of Tianjin University of TCMlung cancer

Start: 2021-02-24Updated: 2022-10-04